Want to see AU:NEU full AI Analyst Report?

Neuren Pharmaceuticals Limited (NEU) Price & Analysis

286 Followers

NEU Stock Chart & Stats

AU$16.46

AU$0.24(1.46%)

At close: Jul 27 4:00 PM EDT

AU$16.46

AU$0.24(1.46%)

Day’s Range― - ―

52-Week RangeAU$11.00 - AU$23.76

Previous CloseN/A

Volume311.36K

Average Volume (3M)305.98K

Market Cap

AU$2.55B

Enterprise ValueAU$1.97K

Total Cash (Recent Filing)AU$286.54M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)131.3

Beta2.72

Next Earnings

Feb 24, 2027

EPS Estimate

0.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.16

Shares Outstanding126,773,980

10 Day Avg. Volume278,541

30 Day Avg. Volume305,983

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)7.05

Price to Sales (P/S)36.92

P/FCF Ratio19.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$25.92

Price Target Upside57.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)0.35

Revenue Forecast (FY)AU$122.02M

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetA large cash balance and debt-free structure give Neuren the capacity to fund NNZ-2591 development and corporate needs internally, reducing dilution risk and preserving flexibility through clinical and regulatory cycles.

DAYBUE Royalty GrowthNeuren benefits from an asset-light royalty model tied to an approved therapy. Rising DAYBUE sales, broader adoption and European and Japanese expansion can support recurring royalties and future milestone receipts.

Pipeline OptionalityProgressing NNZ-2591 into Phase III creates a meaningful second value driver beyond DAYBUE royalties. Success in rare pediatric disorders could expand Neuren’s partnered revenue base and support additional licensing opportunities.

Bears Say

Revenue VolatilityDespite high margins and recent profitability, uneven revenue performance reduces visibility into earnings durability. Dependence on partner milestones and commercial timing may produce fluctuations that complicate long-term financial planning.

HIE Regulatory DelayThe additional study delays clinical entry and extends the time before HIE can contribute to the pipeline. It also demonstrates that regulatory requirements can materially lengthen development timelines and increase program costs.

Koala Execution RiskA complex placebo-controlled Phase III design and reliance on two co-primary endpoints increase execution risk. Slower recruitment or an unfavorable result could defer or reduce the commercial value of NNZ-2591.

Neuren Pharmaceuticals Limited News

Neuren Pharmaceuticals Declares Interim Dividend for June 2026 Half

The latest announcement is out from Neuren Pharmaceuticals Limited ( ($AU:NEU) ). Neuren Pharmaceuticals Limited has declared a...

2d ago

Neuren launches first dividend as DAYBUE royalties and rare-disease pipeline gather pace

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has issued an announcement. Neuren Pharmaceuticals has launched its first-ever dividend program,...

2d ago

Neuren lifts revenue, trims profit as R&D surge underpins first dividend

An announcement from Neuren Pharmaceuticals Limited ( ($AU:NEU) ) is now available. Neuren Pharmaceuticals reported an 8% rise...

2d ago

Neuren Set for European Windfall as Rett Drug DAYBU Wins EU Approval

The latest update is out from Neuren Pharmaceuticals Limited ( ($AU:NEU) ). Neuren Pharmaceuticals’ exclusive licensee, Acadia Pharmaceuticals,...

3d ago

Neuren to Brief Investors on H1 2026 Results as Rare Neurology Pipeline Advances

The latest update is out from Neuren Pharmaceuticals Limited ( ($AU:NEU) ). Neuren Pharmaceuticals will host an investor...

7d ago

Neuren lifts royalty outlook as DAYBUE sales hit record and global rollout advances

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has shared an update. Neuren Pharmaceuticals reported strong second-quarter performance driven by...

23d ago

Neuren deepens rare disease push as Phase 3 PMS trial gains momentum

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has issued an update. Neuren Pharmaceuticals underscored its deepening engagement with the...

1M ago

Neuren Set for Major EU Milestone as EMA Backs DAYBU for Rett Syndrome

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has provided an announcement. Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has secured a...

2M ago

Neuren Pharmaceuticals Seeks ASX Quotation for 450,000 New Shares

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has shared an announcement. Neuren Pharmaceuticals has applied to the ASX for...

2M ago

Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) just unveiled an update. Neuren Pharmaceuticals has notified the market of the...

3M ago

NEU FAQ

What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?

Neuren Pharmaceuticals Limited lowest share price was AU$11.00 and its highest was AU$23.76 in the past 12 months.

What is Neuren Pharmaceuticals Limited’s market cap?

Neuren Pharmaceuticals Limited’s market cap is AU$2.55B.

When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?

Neuren Pharmaceuticals Limited’s upcoming earnings report date is Feb 24, 2027 which is in 180 days.

How were Neuren Pharmaceuticals Limited’s earnings last quarter?

Neuren Pharmaceuticals Limited released its earnings results on Aug 25, 2026. The company reported AU$0.038 earnings per share for the quarter, missing the consensus estimate of AU$0.089 by -AU$0.051.

Is Neuren Pharmaceuticals Limited overvalued?

According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neuren Pharmaceuticals Limited pay dividends?

Neuren Pharmaceuticals Limited does not currently pay dividends.

What is Neuren Pharmaceuticals Limited’s EPS estimate?

Neuren Pharmaceuticals Limited’s EPS estimate is 0.28.

How many shares outstanding does Neuren Pharmaceuticals Limited have?

Neuren Pharmaceuticals Limited has 126,773,980 shares outstanding.

What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?

Neuren Pharmaceuticals Limited reported an EPS of AU$0.038 in its last earnings report, missing expectations of AU$0.089. Following the earnings report the stock price went down -10.564%.

Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in AU:NEU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neuren Pharmaceuticals Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

8.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Neuren Pharmaceuticals Limited (NEU) Earnings & Revenues

Historic Earnings Reports

NEU Company Deck

NEU Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong commercial and financial momentum driven by DAYBUE (cash USD 287M, H1 royalties USD 23M, upgraded guidance and European approval), initiation of a fully franked dividend program, and meaningful progress on NNZ-2591 (Koala Phase III recruitment momentum, Priority Review Voucher value). Challenges include a regulatory-driven delay for HIE (juvenile animal study), remaining execution risk and timeline uncertainty for the placebo-controlled Koala trial (two co-primary endpoints and enrollment duration), and some disclosure gaps on European milestone detail. On balance the positives — robust cash position, confirmed funding for programs, recurring royalties, tangible commercial milestones and increasing product uptake — materially outweigh the setbacks and schedule risks.View all AU:NEU earnings summaries

NEU Stock 12 Month Forecast

Average Price Target

AU$25.92

▲(57.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"AU$11","20":"AU$20","29":"AU$29","15.5":"AU$15.5","24.5":"AU$24.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$28.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$25.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$24.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,15.5,20,24.5,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18,18.838461538461537,19.676923076923078,20.515384615384615,21.353846153846153,22.192307692307693,23.03076923076923,23.869230769230768,24.707692307692305,25.546153846153846,26.384615384615383,27.223076923076924,28.06153846153846,{"y":28.9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18,18.608846153846155,19.217692307692307,19.826538461538462,20.435384615384613,21.04423076923077,21.653076923076924,22.261923076923075,22.87076923076923,23.479615384615386,24.088461538461537,24.697307692307692,25.306153846153848,{"y":25.915,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18,18.5,19,19.5,20,20.5,21,21.5,22,22.5,23,23.5,24,{"y":24.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.61,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.77,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.34,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.65,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >